-
Something wrong with this record ?
Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes
A. Rulcova, I. Prokopova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak, J. Blahos, P. Pavek
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2003 to 1 year ago
Wiley Free Content
from 2003 to 2022
ROAD: Directory of Open Access Scholarly Resources
from 2003
- MeSH
- Transcriptional Activation MeSH
- Anticoagulants chemistry pharmacology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Gene Expression Regulation, Enzymologic drug effects MeSH
- Genes, Reporter MeSH
- Fluorescence Resonance Energy Transfer MeSH
- Stereoisomerism MeSH
- Receptors, Steroid drug effects MeSH
- Cytochrome P-450 Enzyme System genetics MeSH
- Two-Hybrid System Techniques MeSH
- Up-Regulation drug effects MeSH
- Warfarin chemistry pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
UNLABELLED: Background: Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-warfarin. The S-enantiomer has three to five times greater anticoagulation potency than its optical congener. Recently, vitamin K2 function has been proposed via the pregnane X receptor (PXR) in osteocytes. PXR acts as a xenobiotic sensor that controls expression of many genes involved in drug/xenobiotic metabolic clearance. OBJECTIVE: The aim was to examine whether enantiomers of warfarin stereoselectively interact with PXR to up-regulate main drug/xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily. METHODS: Interactions of warfarin enantiomers with PXR were tested by gene reporter assays and time-resolved fluorescence resonance energy transfer technology (TR-FRET) ligand binding assay. Up-regulation of PXR-target gene mRNAs by warfarin enantiomers was studied using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) in primary human hepatocytes. RESULTS: We found that R-warfarin interacts with the PXR nuclear receptor. Consistently, R-warfarin significantly induced CYP3A4 and CYP2C9 mRNAs in cultures of primary human hepatocytes or in LS174T intestinal cells. On the other hand, S-warfarin is a less potent inducer of PXR-target genes in human hepatocytes and activates PXR only at supraphysiological concentrations. In addition, we showed that racemic 10- and 4'-hydroxywarfarins are also highly potent PXR ligands and inducers of CYP3A4 and CYP2C9 mRNA in human hepatocytes. CONCLUSION: We showed that R-warfarin can significantly up-regulate major drug-metabolizing enzymes CYP3A4 and CYP2C9 in the liver and thus may cause drug-drug interactions (DDI) with co-administered drugs. The results warrant reconsideration of racemic warfarin usage in clinics.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027375
- 003
- CZ-PrNML
- 005
- 20250318105631.0
- 007
- ta
- 008
- 120816s2010 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1538-7836.2010.04036.x $2 doi
- 035 __
- $a (PubMed)20735727
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Rulcova, A $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
- 245 10
- $a Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes / $c A. Rulcova, I. Prokopova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak, J. Blahos, P. Pavek
- 520 9_
- $a UNLABELLED: Background: Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-warfarin. The S-enantiomer has three to five times greater anticoagulation potency than its optical congener. Recently, vitamin K2 function has been proposed via the pregnane X receptor (PXR) in osteocytes. PXR acts as a xenobiotic sensor that controls expression of many genes involved in drug/xenobiotic metabolic clearance. OBJECTIVE: The aim was to examine whether enantiomers of warfarin stereoselectively interact with PXR to up-regulate main drug/xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily. METHODS: Interactions of warfarin enantiomers with PXR were tested by gene reporter assays and time-resolved fluorescence resonance energy transfer technology (TR-FRET) ligand binding assay. Up-regulation of PXR-target gene mRNAs by warfarin enantiomers was studied using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) in primary human hepatocytes. RESULTS: We found that R-warfarin interacts with the PXR nuclear receptor. Consistently, R-warfarin significantly induced CYP3A4 and CYP2C9 mRNAs in cultures of primary human hepatocytes or in LS174T intestinal cells. On the other hand, S-warfarin is a less potent inducer of PXR-target genes in human hepatocytes and activates PXR only at supraphysiological concentrations. In addition, we showed that racemic 10- and 4'-hydroxywarfarins are also highly potent PXR ligands and inducers of CYP3A4 and CYP2C9 mRNA in human hepatocytes. CONCLUSION: We showed that R-warfarin can significantly up-regulate major drug-metabolizing enzymes CYP3A4 and CYP2C9 in the liver and thus may cause drug-drug interactions (DDI) with co-administered drugs. The results warrant reconsideration of racemic warfarin usage in clinics.
- 650 _2
- $a antikoagulancia $x chemie $x farmakologie $7 D000925
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x genetika $7 D003577
- 650 _2
- $a rezonanční přenos fluorescenční energie $7 D031541
- 650 _2
- $a regulace genové exprese enzymů $x účinky léků $7 D015971
- 650 _2
- $a reportérové geny $7 D017930
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a steroidní receptory $x účinky léků $7 D011987
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a aktivace transkripce $7 D015533
- 650 _2
- $a techniky dvojhybridového systému $7 D020798
- 650 _2
- $a upregulace $x účinky léků $7 D015854
- 650 _2
- $a warfarin $x chemie $x farmakologie $7 D014859
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Prokopova, I $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
- 700 1_
- $a Krausová, L. $7 _AN046283 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
- 700 1_
- $a Bitman, Michal $7 xx0330075 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
- 700 1_
- $a Vrzal, Radim $7 xx0118949 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University in Olomouc, Slechtitelu, Olomouc
- 700 1_
- $a Dvořák, Zdeněk, $d 1974- $7 xx0118950 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University in Olomouc, Slechtitelu, Olomouc
- 700 0_
- $a Blahoš, Jaroslav $7 xx0179439 $u Laboratory of Molecular Pharmacology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska, Prague, Czech Republic
- 700 1_
- $a Pávek, Petr $7 xx0093070 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
- 773 0_
- $w MED00007070 $t Journal of thrombosis and haemostasis $x 1538-7836 $g Roč. 8, č. 12 (2010), s. 2708-2717
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20735727 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20250318105628 $b ABA008
- 999 __
- $a ok $b bmc $g 949417 $s 784721
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 8 $c 12 $d 2708-2717 $i 1538-7836 $m Journal of thrombosis and haemostasis $n J Thromb Haemost $x MED00007070
- LZP __
- $b NLK112 $a Pubmed-20120816/11/02